IsoRay (ISR) : Starfire Investment Advisers added new position in IsoRay during the most recent quarter end. The investment management firm now holds 21,285 shares of IsoRay which is valued at $14,900 , the company said in a statement filed on Oct 17, 2016 with the SEC.IsoRay makes up approximately 0.01% of Starfire Investment Advisers’s portfolio.
Other Hedge Funds, Including ,
IsoRay closed down -0.0001 points or -0.01% at $0.7 with 1,25,130 shares getting traded on Friday. Post opening the session at $0.7001, the shares hit an intraday low of $0.7 and an intraday high of $0.7099 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
IsoRay Inc. develops manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in treatment for all solid tumors using Cesium-131. Cesium-131 is a radioactive isotope that can be produced by the neutron bombardment of Barium-130 (Ba-130). The Company’s product candidate is Proxcelan Cesium-131. The Company markets the Proxcelan Cesium-131 brachytherapy seed for the treatment of prostate cancer; brain cancer; lung cancer; head and neck cancers; gynecological cancer: pelvic/abdominal cancer; colorectal cancer and ocular melanoma. It also markets the GliaSite RTS for the treatment of brain cancer such as primary and recurrent gliomas and metastic brain tumors. GliaSite RTS is a cleared balloon catheter device. The components included in the GliaSite RTS are the GliaSite Catheter Tray GliaSite Access Tray Iotrex Solidifier and either Iotrex or Cesitrex as the radiotherapy solution.